Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -748.35% is 20% above its 5-year average of -935.66%, around the middle of its 5-year range (-1691.69%–-223.50%).
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2025 (2025-03-31): -223.50%.
EBITDA MARGIN
-748.35%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
-1080.07%
EBITDA MARGIN AVG 5Y
-935.66%
EBITDA MARGIN AVG 10Y
-759.61%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+30.71%
CURRENT VS 5Y AVG
+20.02%
CURRENT VS 10Y AVG
+1.48%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Oramed Pharmaceuticals Inc.
Market Cap
$181.63M
EBITDA Margin
-748.35%
TTM Avg
N/A
3Y Avg
-1080.07%
5Y Avg
-935.66%
Market Cap
$183.94M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$178.36M
EBITDA Margin
-5219.12%
TTM Avg
-6964.15%
3Y Avg
-7000.85%
5Y Avg
-5161.09%
Market Cap
$175.46M
EBITDA Margin
-6455.53%
TTM Avg
-6455.53%
3Y Avg
-6455.53%
5Y Avg
-6455.53%
Market Cap
$188.72M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.76M
EBITDA Margin
-258.92%
TTM Avg
-202.75%
3Y Avg
-649.71%
5Y Avg
-1766.39%
Market Cap
$172.51M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$172.29M
EBITDA Margin
-6.19%
TTM Avg
-12.15%
3Y Avg
-13.37%
5Y Avg
-13.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oramed Pharmaceuticals Inc. (ORMP) | $181.63M | -748.35% | N/A | -1080.07% | -935.66% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $182.11M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $178.36M | -5219.12% | -6964.15% | -7000.85% | -5161.09% |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.46M | -6455.53% | -6455.53% | -6455.53% | -6455.53% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.72M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | -258.92% | -202.75% | -649.71% | -1766.39% |
| Precision BioSciences, Inc. (DTIL)vs › | $172.51M | -144.16% | -87.79% | -115.19% | -149.65% |
| Journey Medical Corporation (DERM)vs › | $172.29M | -6.19% | -12.15% | -13.37% | -13.97% |
| Cue Biopharma, Inc. (CUE)vs › | $171.44M | -83.89% | -252.72% | -1380.70% | -1383.45% |
Gross Margin
0.7%
EBITDA Margin
-748.4%
Operating Margin
-754.4%
Net Margin
3202.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-03-31 | -223.50% |
| 2023-06-30 | -554.75% |
| 2023-03-31 | -776.43% |
| 2022-12-31 | -1427.75% |
| 2022-09-30 | -1198.53% |
| 2022-06-30 | -1691.69% |
| 2022-03-31 | -1687.84% |
| 2021-11-30 | -1194.07% |
| 2021-08-31 | -1082.14% |
| 2021-05-31 | -894.27% |
| 2021-02-28 | -727.82% |
| 2020-11-30 | -864.24% |
| 2020-08-31 | -442.73% |
| 2020-05-31 | -333.48% |
| 2020-02-29 | -598.66% |
| 2019-11-30 | -360.39% |
| 2019-08-31 | -343.76% |
| 2019-05-31 | -595.01% |
| 2019-02-28 | -535.44% |
| 2018-11-30 | -688.13% |
| 2018-08-31 | -510.21% |
| 2018-05-31 | -734.68% |
| 2018-02-28 | -514.74% |
| 2017-11-30 | -446.97% |
| 2017-08-31 | -461.49% |
| 2017-05-31 | -348.95% |
| 2017-02-28 | -550.57% |
| 2016-11-30 | -392.95% |
| 2016-08-31 | -1002.27% |
| 2016-05-31 | -1293.87% |
| 2016-02-29 | -1528.80% |
| 2015-11-30 | -301.48% |
| 2014-05-31 | -501.87% |
| 2012-02-29 | -2168.08% |
